Saturday 17 October 2026
Export ATXI’s income statement to Excel — free account
Avenue Therapeutics, Inc.
ATXI Healthcare Biotechnology
Avenue Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million. In the quarter to June 2026, EPS fell 290.9% and free cash flow fell 169.9%, each against the same quarter a year earlier.
0.43
0.00
0.00%
Follow ATXI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
37.93% | (157.75%) | (99.26%) | (163.30%) | |
| 23.62% | (103.84%) | (57.80%) | (90.50%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
32.57% | (158.79%) | (146.24%) | (488.05%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.55) | (0.59) | (0.33) | (0.42) | |
Free Cash Flow |
(1.74) | (1.83) | (1.08) | (1.38) | |
| Other line items | |||||
Cash ROIC |
(28.99%) | (39.11%) | (30.01%) | (55.12%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
(2.32) | 0.63 | 0.62 | 0.50 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.55) | (0.59) | (0.33) | (0.42) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates